relentless medicine discovery.

Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.

C U G G A U C
C U G G A U C
C U G G A U C
C U G G A U C
C U G G A U C
C U G G A U C
C U G G A U C
Invos Global

—We aim to improve the probability of making impactful medicine a reality. Through a culture of innovative problem-solving, our team expedites the discovery of promising drugs to drive real change in our lifetime.

Tangram integrates computational power and biology to accelerate the discovery of life-transforming RNAi medicines.

Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
Invos Clients
About

GENETIC MEDICINES FASTER

Underpinned by our extensive data foundation, we are continually enhancing our understanding of biology through computational drug discovery. Tangram identifies and pursues unexplored targets backed by robust biological data.

Invos Global About
Approach

SCIENCE THAT DOESN’T SLOW DOWN

Tangram’s powerful composition of unconventional thinkers, computation, and biological data rapidly realizes life-transforming RNAi medicines. With our LLibra and GalOmic technologies, the Tangram team relentlessly focuses on finding and pursuing the right targets through AI drug discovery.

News

PRESS RELEASES

Explore insights and breakthroughs. See the newest activity in relentless medicine discovery.

Press Release

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

Apr 7, 2025

Press Release

Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

May 7, 2025

Press Release

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

June 7, 2025

Press Release

e-therapeutics presents new data supporting ETX‑312 as a differentiated, disease-modifying near-clinic GalOmic Treatment for MASH

May 7, 2024

/
Invos Global About
Careers

JOIN US

If you want see beyond how things have been done before, join the Tangram team. You’ll be supported to find the insight that will make the difference. To rapidly realize life-transforming RNAi medicines.